We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to ...

Proficio Capital Partners LLC bought a new stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) during ...

If you work in the biotech industry, you might know the name Alex Denner. If not, his name probably doesn’t ring a bell. ...

In this article, we will be taking a look at the 15 best biotech stocks to buy according to billionaires. Although biotech ...

Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) was upgraded by research analysts at StockNews.com from a “buy” rating ...

Topline data from Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected in the third quarter of 2025.Fourth positive DSMB ...

Morgan Stanley assumed coverage of Neurocrine (NBIX) with an Overweight rating and a price target of $150, down from $185. The firm sees ...

Neurocrine Biosciences (NasdaqGS:NBIX) announced the initiation of a Phase 1 clinical study for the compound NBI-1140675, a new VMAT2 inhibitor. This development could influence investor sentiment, ...

Neurocrine Biosciences, Inc. today announced the initiation of a Phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of investigational compound ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

In recent years, Neurocrine has concentrated on expanding its research and development (R&D) capabilities and enhancing its product portfolio. This is evident from the significant investment in ...